Revolutionizing Vaccine Development: Epitope-Based mRNA and Recombinant Protein Vaccines for Breast and Prostate Cancer

At AthenaVax, we are revolutionizing vaccine development with our innovative focus on epitope-based vaccines. Using cutting-edge recombinant protein and mRNA technology, we craft vaccines that target a precise string of peptides, including B cell and T cell epitopes, to generate a robust immune response. By omitting Treg epitopes, we enhance vaccine efficacy, maximizing potential outcomes. Our current focus targets brain cancer, breast cancer and prostate cancer, paving the way for new hope in the fight against these challenging diseases. AthenaVax is committed to advancing cancer treatment through precision and innovation.